Literature DB >> 29968561

Some Necessary Additional Points.

Michael Oertel, Hans-Theodor Eich.   

Abstract

Mesh:

Year:  2018        PMID: 29968561      PMCID: PMC6050430          DOI: 10.3238/arztebl.2018.0417a

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


× No keyword cloud information.
  4 in total

1.  Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.

Authors:  John M M Raemaekers; Marc P E André; Massimo Federico; Theodore Girinsky; Reman Oumedaly; Ercole Brusamolino; Pauline Brice; Christophe Fermé; Richard van der Maazen; Manuel Gotti; Reda Bouabdallah; Catherine J Sebban; Yolande Lievens; Allessandro Re; Aspasia Stamatoullas; Frank Morschhauser; Pieternella J Lugtenburg; Elisabetta Abruzzese; Pierre Olivier; Rene-Olivier Casasnovas; Gustaaf van Imhoff; Tiana Raveloarivahy; Monica Bellei; Thierry van der Borght; Stephane Bardet; Annibale Versari; Martin Hutchings; Michel Meignan; Catherine Fortpied
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

2.  Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.

Authors:  Andreas Engert; Heinz Haverkamp; Carsten Kobe; Jana Markova; Christoph Renner; Antony Ho; Josée Zijlstra; Zdenek Král; Michael Fuchs; Michael Hallek; Lothar Kanz; Hartmut Döhner; Bernd Dörken; Nicole Engel; Max Topp; Susanne Klutmann; Holger Amthauer; Andreas Bockisch; Regine Kluge; Clemens Kratochwil; Otmar Schober; Richard Greil; Reinhard Andreesen; Michael Kneba; Michael Pfreundschuh; Harald Stein; Hans Theodor Eich; Rolf-Peter Müller; Markus Dietlein; Peter Borchmann; Volker Diehl
Journal:  Lancet       Date:  2012-04-04       Impact factor: 79.321

Review 3.  Molecular Imaging in Oncology Using Positron Emission Tomography.

Authors:  Thorsten Derlin; Viktor Grünwald; Jörg Steinbach; Hans-Jürgen Wester; Tobias L Ross
Journal:  Dtsch Arztebl Int       Date:  2018-03-16       Impact factor: 5.594

4.  Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.

Authors:  John Radford; Tim Illidge; Nicholas Counsell; Barry Hancock; Ruth Pettengell; Peter Johnson; Jennie Wimperis; Dominic Culligan; Bilyana Popova; Paul Smith; Andrew McMillan; Alison Brownell; Anton Kruger; Andrew Lister; Peter Hoskin; Michael O'Doherty; Sally Barrington
Journal:  N Engl J Med       Date:  2015-04-23       Impact factor: 91.245

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.